6th PROGRAM

Day’s Theme: The Creative Process and Technology Assessment


 

  • 8:30 AM | Registration/Administrative Continental Breakfast

 


 

  • 9:00 AM | Session 1:  Welcome and Opening Remarks:

 

Prof. Moshe Zviran, Vice Dean Faculty of Management, Tel Aviv University

 

Course Directors:

 

Introduction to Program Structure

Review of required assignments

 


 

  • 9:30 AM  | Session 2:  The Persuasive Pitch, Part 1: Introduction of course participants

 

Benny Zeevi, M.D. Managing General Partner, DFJ Tel Aviv Venture Partners

 

David Frank, Managing Director MEDX Associates LLC – “Making YOUR Pitch Persuasive”

 

In order to give participants a chance to learn more about their colleagues in the course, and as the first part of our special focus on presentations, we are asking each participant to prepare to deliver a 3-5 minute presentation, using 2-4 power point slides, to introduce yourself and your company to the group

 


 

  • 11:20AM | Session 3: Keynote Address – Innovation and the Israeli Life Sciences Induartry

Benny Zeevi, M.D. Managing General Partner, DFJ Tel Aviv Venture Partners

 


 

  • 12:00PM  | Bio Break

 


 

  • 12:15PM  | Session 4:  Project, Product or Company?: Assessment and Qualification of Technologies as a Basis for a Startup

 

The successful translation of discoveries from the lab to the market is the greatest challenge facing an entrepreneur. Many companies are formed on technologies emanating from university laboratories and spinouts from major corporations as well as life science companies themselves. Many healthcare innovations fall because they neither integrate with existing clinical practice nor are successful in creating new ones. Forming a company around a technology is relatively easy. Staffing and capitalizing it is another story. Savvy employees, astute venture capitalist and selective prospective strategic partners know that companies without technological critical mass sufficient to bring a series of product to the market are unsustainable. This session will provide tools and a contextual framework as to how technologies can be assessed by academic founders, top industry executives, CSOs, Incubators and VCs so that they can orient and characterize their business for capitalization and partnering.

 

Moderator: Benny Zeevi, M.D., Managing General Partner, DFJ Tel Aviv Venture Partners

Stephen M. Sammut, Senior Fellow, Health Care Systems and Entrepreneurial  Programs, Wharton School, University of Pennsylvania

David Frank, Managing Director MEDX Associates LLC

Tamara Mansfeld, Director, Strategy & Portfolio Management, Pfizer

 


 

  • 1:50 PM | Networking Luncheon

 


 

  • 2:40 PM  | Session 5: Lessons learned from our experience: A panel of life science CEOs and Entrepreneurs

 

In this session we will have several US and Israeli CEOs in life sciences sharing their experience.

 

Specifically addressing issues: Building a management team, financing, collaborations, dealing with the board and more

Moderator: Ruti Alon, General Partner, Pitango Venture Capital Fund

 

Udi Cohen, CEO Biocontrol

 

Ascher Shmulewitz, M.D., President Medegenesis

 


 

  • 4:00 PM | Session 6 : Case Study

Given Imaging – The Quest for Quantum Leap

Faculty led discussion of a case

Stephen M. Sammut, Senior Fellow, Health Care Systems and Entrepreneurial  Programs, Wharton School, University of Pennsylvania

 


 

  • 4:50PM |  Bio Break

 


 

  • 5.00PM | Keynote Address: Corie Bar Dea, Strategy Director, Designit

“Innovation Strategy”

 


 

  • 5:45 PM | Session 7: Market Analysis and Competitive Analysis – Essentials of Marketing in Biotechnology and Medical Devices

 

This session will focus on Market analysis, Clinical state of the art and product positioning: assessment of different applications for the same product (choosing the right application from commercial point of view), Determination of subgroup of patients most appropriate for the product, Competitive analysis, Pricing and reimbursement strategy, Importance of opinion leaders, patients groups, patients organization and  Selling strategy.

 

Moderator:

Stephen M. Sammut, Senior Fellow, Health Care Systems and Entrepreneurial  Programs, Wharton School, University of Pennsylvania

 

David Frank, Managing Director MEDX Associates LLC

 

Yael Glassman, Former VP Marketing, American Well

 


 

  • 7:30 PM | End of Day…

 


Day’s Theme: The Creative Process and Technology Assessment


 

  • 8:30 AM | Continental Breakfast

 


 

  • 9:00 AM | Session 9: Biotechnology and Medical device Regulatory Planning, Clinical Development and the Implications for Strategy and Financing: From Proof of Concept to Marketing Success. Designing and conducting clinical trialsThis session provides an abbreviated view of the overall process and specific insight into planning for FDA regulations in light of strategy, financial needs, and the concerns of prospective partners and investors. Entrepreneurs need to understand that there is an increasing need to perform clinical studies to support medical device safety and performance claims. They also need to have a basic understanding of the activities, resources and costs associated with the design and conduct of clinical studies. The failure to incorporate an effective clinical strategy into new project planning can lead to significant project and funding delays or, worse, the failure of the project. This session will provide an overview of the increasing need for device clinical study data; key activities, resource needs and costs; and planning for the successful design and conduct of medical device clinical studies for acceptance in the United States and Europe, even when these studies are conducted outside of these regulatory jurisdictions.Moderator: Benny Zeevi, M.D. Managing General Partner, DFJ Tel Aviv Venture PartnersSusan Alpert, PhD, MD, Former Senior Vice President, Chief Regulatory Officer of Medtronic, FormerVice President of Regulatory Sciences for C.R. Bard, Inc, previously worked at FDA where she held a variety of positions in the Centers dealing with drugs, devices and radiological health, and foods, including six years as the Director of the Office of Device Evaluation.Udi Cohen, CEO Biocontrol – The experience of a CEO in conducting multinational clinical trial

 


 

  • 10:20 AM | Coffee break

 

  • 10:30 AM |Session 10: Keynote LecturePatrick Flochel, Partner, Global Pharmaceutical Sector Leader, Global Life Sciences Centre, EY”New business models in Life Sciences”

 

  • 11:45 | Robert Barzelay, Marketing Consultants, Global Strategists – Marketing *** Session 11: Emerging Markets – Opportunities for Life Science companies The growth of biotechnology and other health related industries in Brazil, China and India is taking place at a stunning pace. While this fact might appear to be a competitive threat to Israeli entrepreneurs, it is in fact an opportunity. Companies in these countries are eager to collaborate with Israeli companies. This session will describe the status of activity in the three most rapidly advancing countries and will also describe how Israeli firms can do business in these same countries.  Moderator: Stephen M. Sammut, Senior Fellow, Health Care Systems and Entrepreneurial  Programs, Wharton School, University of Pennsylvania, Venture Partner, Burrill & Company Gad Berdugo, Managing Director and Head of Life Sciences and Healthcare at Tegris Advisors, Formerly Founder of Explorium Capital and Former Director and Sector Leader for global healthcare investment research at LazardDavid Frank, Managing Director MEDX Associates LLCPatrick Flochel, Partner, Global Pharmaceutical Sector Leader, Global Life Sciences Centre, EYPablo Halpern, CEO Atche Medical, Brazil- Opportunities in the Life Sciences MarketGil Kerbs, New Product Development Marketing manager, Covidien

 

  • 1:00 PM | Session 12: Keynote lecture:Dr. Jeremy Levin, Former President & CEO Teva Pharmaceutical”The role of the company in society”

 

  • 1:45 | Networking Luncheon

 

  • 2:30 PM | Session 13:  Capitalization of a life science Venture –Value inflection Points, Milestones and Capital Requirements, Alternative financing, Terms etc.

 

 Financing a life science venture is challenging. When meeting with investors and prospective strategic partners, entrepreneurs will often hear questions that ask: Where are you in the value chain?” How does your business model reflect this?” “How do you describe your milestones and how are you managing towards them?” How do your milestones tie-in with your value inflection points?”  This session will consist of a brief overview of typical value inflection points for each type of product, classical and alternative ways of financing, terms of financing rounds and more.Moderator: Brent Ahrens, General Partner, Canaan PartnersMike Berman, medical device investor/entrepreneur, past President of the Cardiology business of Boston ScientificBenny Zeevi, M.D. Managing General Partner, DFJ Tel Aviv Venture PartnersJohn R. Lieberman, CPA/PFS  Managing Director Perelson Weiner LLP Gad Berdugo, Managing Director and Head of Life Sciences and Healthcare at Tegris Advisors, Formerly Founder of Explorium Capital and Former Director and Sector Leader for global healthcare investment research at LazardDr. Ayal Shenhav, Shenhav & Co – Crowd funding for life sciences companiesHanan Haviv, Partner, Herzog, Fox & Neeman


 

  • 4:00 | Session 14: Case study

Yotam Levin, MD, MBA,CEO, Nanopass

Optimizing business models for a drug delivery Company

 


 

  • 5:00 PM | Coffee break

 


 

  • 5:15 | Session 15: Intellectual Capital ManagementThe goal of the session is to provide information and insight into the specific issues confronting investigators, entrepreneurs, investors and their patent attorneys. The session will address the formation of specific IP strategy and execution and using intellectual capital for competitive advantage. Content includes major issues confronting companies with US and filings in other jurisdictions related to biotechnology, e.g., patent ownership, non-obviousness rulings, the scope of what can be patented.. A VC will also provide an investor viewpoint.Moderator: Steve M. Sammut, Senior Fellow, Wharton Health Care Systems and EntrepreneurshipBrian Hopkins, Member, Mintz Levin – IP ManagementJohn R. Lieberman, CPA/PFS  Managing Director Perelson WeinerMedical device executiveBrent Ahrens, General Partner, Canaan Partners – The VC perspective

 


 

  • 6:30 PM | Session 16: Incorporating Reimbursement in the Company Development Strategy Moderator: Brent Ahrens, General Partner, Canaan PartnersReggie Williams, Vice President, Avalere HealthMike Berman, medical device investor/entrepreneur, past President of the Cardiology business of Boston Scientific

 


 

  • 8:00 PM | End of the day…

Day’s Theme: Bringing the product to the market and HCIT


 

 

  • 8:30 AM | Continental Breakfast

 


 

  • 9:00 AM | Session 17: Biopharmaceutical and Medical Device Licensing, Partnering and Strategic Alliances Format: Brief lectures, panel discussion, Q&AMajor practical issues in formulation of partnering goals and managing different types of strategic alliances,  preparation for positioning for partnering, identifying and qualifying prospective partners,  making the approach, negotiation, closing the deal, with special emphasis on how to design alliances and avoid many potential problems and complications in managing these relationship.Moderator: Benny Zeevi, M.D. Managing General Partner, DFJ Tel Aviv Venture PartnersDavid Frank, Managing Director MEDX Associates LLCEd  Saltzman, President DefinedHealthMike Berman, medical device investor/entrepreneur, Former President of the Cardiology business of Boston ScientificMaya Racine – Netser, Adv, Partner, Head, technology licensing group in the High Tech Practice ,  Herzog, Fox & NeemanDiscussion and Q&A

 


 

  • 11:00 AM | Bio – Break

 


 

  • 11:30 AM | Session 18: Healthcare IT and Digital Health

 

 Quality and efficient healthcare delivery is highly depended on information and communication, anytime anywhere.Despite Healthcare Delivery Industry having much to gain from Information and Communication Technologies; it is the slowest from all industries in the adoption. HCIT investment will only be successful if the fit between IT and clinical processes will be close to matching, which will be reflected by the acceptance or rejection of end users. The emergence of new, disruptive technologies plays a crucial role in closing the capability gap and gaining more acceptances from the main users. The latest innovations are changing not only how the medical care is organised, practiced and delivered but are also redefining host of other qualities including changing patient-physician model and facilitating the emergence of new industry players within the value chain.Mobile devices and services are transforming the way people all over the globe live, work, play and now also revolutionize the way they receive medical care. Mobile devices are the most personal technology that consumers and healthcare providers own, and allow consumers to be introduced to new services quickly and intuitively and establish personal preferences. Digital health enables health and wellness to be delivered through mass personalization anywhere and anytime, in the comfort of patients’ own homes and during daily routines. Many new players are entering the mobile health industry; it is highly fragmented market worth several billion of dollars. The adoption and deployment of mHealth requires new regulatory clarity, standards and interoperability of devices and software, new viable business models, consumers and provider’s cultural changes and proven evidence –based outcome measures, clinically and economically.The potential applications of HCIT technologies and digital health, it’s role in global health, new business models, the use of social media by pharma and medical device companies as well as by healthcare providers and insurance companies and regulatory issues will be discussed. Moderator and introduction: Benny Zeevi, M.D. Managing General Partner, DFJ Tel Aviv Venture PartnersPatrick Flochel, Partner, Global Pharmaceutical Sector Leader, Global Life Sciences Centre, EYMichal Geva, Co-Founder & Managing  Partner, TriVenturesYael Glassman, VP Marketing and Business Development, SensibleSusan Alpert, PhD, MD, Former Senior Vice President, Chief Regulatory Officer of Medtronic, FormerVice President of Regulatory Sciences for C.R. Bard, Inc., previously worked at FDA-Are Digital and Mobile Health Tools Medical Devices? Who’s Opinion Counts?


 

  • 2:00 PM | Luncheon

 


 

  • 2:45 PM | Session 18 – continue

 


 

  • 3:30 PM | Coffee break

 


 

  • 3:45 – 4:30 PM | Session 19: Case StudyMarketing case studyRobert Barzelay, Marketing Consultants, Global Strategists

 


 

  • 4:30 – 5:30 PM | Case study- American Well Yael Glassman, VP Marketing and Business Development, SensibleBenny Zeevi, M.D. Managing General Partner, DFJ Tel Aviv Venture Partners

 


 

  • 5:30 – 6:00 PM | Bio Break

 


 

  • 6:00 PM | The Persuasive Pitch, Part 2: Presentations Workshop

Moderators: Steve M. Sammut, Senior Fellow, Wharton Health Care Systems and EntrepreneurshipBrent Ahrens, General Partner, Canaan PartnersBenny Zeevi, M.D. Managing General Partner, DFJ Tel Aviv Venture PartnersDavid Frank, Managing Director MEDX Associates LLCEllen Lubman, Senior Vice President with Kadmon PharmaceuticalsEd  Saltzman, President DefinedHealthThree to five participants will present revised versions of their introductions from Sunday before a panel of VCs and experts, and will receive feedback on both the content and spoken aspects of their presentations.


 

  • 7:00 | Program AdjournmentSession 22: Teams gather for “Take-aways Exercise”Each participant will receive at registration a work-sheet to record for each session one major lesson or “take-away.” Teams will gather to discuss, compare notes, and develop one major take away for three sessions that will be assigned. Participants will have reviewed take-aways from Days 1 and 2 at the end of each day.